Flucytosine
| Drug Category | Drug | IHD Dosing | Administration Timing Around HD Session |
|---|---|---|---|
| Antifungals | Flucytosine | 37.5mg/kg PO QHD | Administer Post-HD |
Molecular Weight (Da) | Excreted Unchanged (%) | Normal Half-Life (Hours) | ESRD Half-Life (Hours) | Plasma Protein Binding (%) | Volume of Distribution (L/kg) | Dialytic Plasma Clearance (ml/min) | % Dialyzed |
|---|---|---|---|---|---|---|---|
| 129 | 90 | 3-6 | 75-200 | <10 | 0.6 | N/A | Readily (low flux) |
References:
- Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians;2007.
- Banks R, Williams A, Glover S, Burton P, Warnock D, Mackenzie C. Disseminated cryptococcosis in a patient receiving chronic haemodialysis. Postgraduate medical journal 1985; 61(718), 745-7.
- Block E, Bennett J, Livoti L, Klein W. Flucytosine and Amphotericin B: Hemodialysis Effects on the Plasma Concentration and Clearance. Annals of internal medicine 1974; 80, 613-7.
- Christopher T, Graham, Blair A, Forrey A, Cutler R. Hemodialyzer Clearances of Gentamicin, Kanamycin, and Flucytosine, with a Technique for Planning Therapy. Journal of Pharmacokinetics and Biopharmaceutics 1976; 4(5), 427-41.
- DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB01099
- Gandhi B, Bahadur M, Dodeja H, Aggrwal V, Thamba A, Mali M. Systemic fungal infections in renal diseases. Journal of postgraduate medicine 2005; 51(Suppl 1), S30-6.
- Polak A. Pharmacokinetics of amphotericin B and flucytosine. Postgraduate medical journal 1979; 55(September), 667-670.